LeadInvent Pharma

LeadInvent Pharma is a nanomedicine company developing GBGe, a proprietary light-activated nanoparticle platform that leverages photodynamic therapy to generate reactive oxygen species for targeted cancer cell destruction, with potential applications in post-surgical tumour treatment and broader oncology and dermatology indications.

TreatmentMVPUnited States

Request an introduction Visit website LinkedIn

See the full profile

The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.

Company info

Countries of Operation: India
Founding Year: 2019
Number of Employees: 6–10

Company overview

Full Description: **LeadInvent Pharma Inc. — Company Description** LeadInvent Pharma Inc. is a nanomedicine company developing innovative light-activated therapies based on photodynamic therapy (PDT). Its proprietary platform, GBGel™, combines engineered nanoparticles containing an EMA-approved photosensitizing drug with a medical-grade gel. When activated by specific wavelengths of light, the formulation generates singlet oxygen and other reactive oxygen species (ROS), inducing targeted cell death while potentially limiting systemic exposure. The company's initial focus is improving brain cancer surgery outcomes, particularly in glioblastoma, by targeting residual malignant cells following tumour resection. GBGel is designed for local application to the surgical cavity followed by laser activation. The platform has demonstrated preclinical proof of concept in brain cancer models, and LeadInvent has engaged with the US FDA through a Pre-IND meeting. Future opportunities include other solid tumours and topical dermatological applications, subject to further validation. The company is seeking pharmaceutical and biotechnology partners for licensing, co-development, and potential acquisition of its platform technology.
Areas of focus: Oncology, photodynamic therapy, Adjuvant to surgery
Problem Statement: Surgical removal of solid tumours often leaves behind microscopic cancer cells at the margins of the resection cavity. These residual malignant cells can survive conventional treatment and contribute to tumour recurrence, limiting the effectiveness of surgery, particularly in aggressive cancers such as glioblastoma. Existing treatment options may not adequately eliminate these residual cells without risking damage to surrounding healthy tissue. LeadInvent Pharma aims to address this unmet need through GBGel™, a locally applied, light-activated nanomedicine platform designed to generate reactive oxygen species (ROS) and destroy residual cancer cells following tumour resection. The platform also presents an opportunity to explore localized photodynamic treatments for dermatological conditions and other indications where targeted cellular or antimicrobial activity may offer therapeutic value.

Interested in this innovator?

Send a short message. We’ll pass it to LeadInvent Pharma with your name and email, so they can reply.

Request an introduction

Create an account or log in to send this request. Already a member? Log in

Introductions to innovators are open to innovators, investors, mentors and corporates.

LeadInvent Pharma

Company info

Company overview

Interested in this innovator?

Product & IP

Team

Online presence

Materials